San Diego, California, USA, November 15, 2026
Viking Therapeutics, Inc. has presented new clinical findings from its VK2735 obesity development programme at ObesityWeek® 2026, highlighting improvements in obesity classification and cardiometabolic health markers following treatment with the investigational drug. The findings come from an exploratory analysis of the Phase 2 VENTURE clinical trial, in which participants received once-weekly subcutaneous injections of VK2735. The analysis found that 74% of participants treated with VK2735 improved by at least one body mass index (BMI) category after 13 weeks, compared with 15% of participants receiving placebo. The treatment group also demonstrated improvements in several cardiometabolic measurements, including waist circumference, fasting glucose, insulin, blood pressure, triglycerides, and low-density lipoprotein cholesterol. VK2735 is an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, being developed in both injectable and oral formulations for obesity and other metabolic disorders. Viking also presented baseline characteristics from its ongoing Phase 3 VANQUISH-2 study, which is evaluating weekly injectable VK2735 in adults with overweight or obesity and type 2 diabetes. Together, the presentations provide an update on the company’s clinical development strategy and the potential metabolic effects of dual GLP-1/GIP receptor activation.
VK2735 Shows Improvements in BMI Categories
The exploratory VENTURE analysis evaluated changes in obesity severity among participants receiving weekly subcutaneous VK2735 over a 13-week treatment period. Results showed that 74% of treated participants moved into a lower BMI category, compared with 15% in the placebo group. Importantly, none of the participants receiving VK2735 experienced an increase in BMI category during the analysis period. The findings included improvements across different baseline obesity classifications. Among participants who began with Class III obesity, 57% moved into Class II and 11% moved into Class I obesity. Among those with Class II obesity, 80% transitioned into Class I and 2% moved into the overweight category. In the Class I obesity group, 65% transitioned into the overweight category and 9% reached the normal-weight category. These findings suggest that treatment-associated weight reduction was accompanied by measurable changes in obesity classification. However, BMI category transitions represent an exploratory outcome and should not be interpreted as evidence of long-term weight maintenance or reduced disease complications.
Cardiometabolic Markers Improve Alongside Weight Reduction
The analysis also examined changes in cardiometabolic measurements among participants whose BMI category improved and those whose category remained unchanged. Participants who improved by at least one BMI category demonstrated greater reductions in several measured risk markers. These included waist circumference, fasting glucose, triglycerides, systolic and diastolic blood pressure, and LDL cholesterol. Among participants with a BMI category improvement, mean waist circumference decreased by 10.1 centimetres, compared with 7.7 centimetres in participants whose BMI category did not change. Mean glucose decreased by 12.4 mg/dL in the improvement group, while the group without a category change showed a reduction of 10.1 mg/dL. Mean systolic blood pressure declined by 9.0 mmHg and mean LDL cholesterol decreased by 12.3 mg/dL among participants whose BMI category improved. The company also reported reductions in haemoglobin A1c and triglycerides. These results indicate that improvements in obesity severity were accompanied by favourable changes in multiple metabolic measurements during the study period. Viking previously reported that participants receiving weekly VK2735 in the Phase 2 VENTURE trial achieved mean body-weight reductions of up to 14.7% after 13 weeks. Up to 88% of participants in the treatment groups achieved at least 10% weight loss, compared with 4% receiving placebo. The company reported that 92% of drug-related treatment-emergent adverse events were mild or moderate.
Phase 3 VANQUISH Programme Advances Clinical Evaluation
In addition to the VENTURE analysis, Viking presented baseline characteristics from the ongoing Phase 3 VANQUISH-2 clinical trial, which is evaluating subcutaneous VK2735 in adults with overweight or obesity and type 2 diabetes. The presentation indicated that the randomized study population was representative of the adult U.S. population with a BMI of at least 27 kg/m² and type 2 diabetes. The broader VANQUISH programme includes two randomized, double-blind, placebo-controlled, multicentre studies: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Both trials are designed to evaluate once-weekly subcutaneous VK2735 over 78 weeks, with percentage change in body weight as the primary endpoint. Secondary and exploratory measures include the proportions of participants achieving at least 5%, 10%, 15%, and 20% weight loss. The studies also include extension periods that allow continued treatment after the initial dosing period. Viking expects the VANQUISH studies to be completed in 2027. Overall, the new ObesityWeek findings add to the clinical evidence supporting further investigation of VK2735. The candidate remains investigational, and the ongoing Phase 3 trials will be important in determining its long-term safety, efficacy, and potential role in obesity management.
Source: Viking Therapeutics press release



